Hypoglycaemia: current management and controversies
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is a major burden on patients and society and is often a barrier to the achievement of tight glycaemic control. Intact awareness of hypoglycaemia is crucial to recognising and treating hypoglycaemia before it becomes severe enough to impair consciousness. Repeated hypoglycaemia can lead to impaired awareness increasing the risk of severe hypoglycaemia up to sixfold. Hypoglycaemia is much less common in those with type 2 diabetes, the incidence increasing with longer duration of treatment with insulin, associated comorbidities, and in the elderly. Alcohol, advancing age and exercise may predispose to hypoglycaemia. Newer agents acting via the incretin axis are associated with low rates of hypoglycaemia. Intensification of therapy to achieve tight glucose control can increase the risk of hypoglycaemia in the outpatient as well as critical care setting. In some studies this has also been associated with increased mortality, although causality has not been proven. Insulin treated patients are currently restricted from driving heavy goods vehicles or public service vehicles, although it is unclear if those with diabetes have any higher rates of accidents than those without diabetes. Surveys show that professionals are poor at emphasising the Driver and Vehicle Licensing Agency recommendations for drivers with diabetes in the UK. At every visit, patients with diabetes on hypoglycaemic agents should be assessed for frequency, severity, and awareness of hypoglycaemia. The main therapeutic strategies for reducing hypoglycaemia are structured patient education, use of modern insulin analogues, insulin pumps, and continuous glucose monitoring. Transplantation of islets or whole pancreas is indicated in those with recurrent disabling hypoglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119 · cited 1×
“However, subsequent larger multicentre studies of tight glucose control in the critically ill(64) 65 were unable to reproduce these benefits and a large study of over 10 000 patients showed a trend to increased mortality in the intensive treatment arm.(66) All these studies reported higher rates of hypoglycaemia in th…”
ResultGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Intensive insulin therapy and pentastarch resuscitation in severe sepsis
Brunkhorst, F. M., Engel, C., Bloos, F., Meier-Hellmann, A., Ragaller, M., Weiler, N., Moerer, O., Gruendling, M., Oppert, M., Grond, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070716 · Cited by 2,921 · cited 1×
“However, subsequent larger multicentre studies of tight glucose control in the critically ill”
BackgroundStandards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Preiser, J.-C., Devos, P., Ruiz-Santana, S., Mélot, C., Annane, D., Groeneveld, J., Iapichino, G., Leverve, X., Nitenberg, G., Singer, P., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1585-2 · Cited by 911 · cited 1×
“However, subsequent larger multicentre studies of tight glucose control in the critically ill”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Hypoglycaemia (literally low blood glucose concentration) and the fear it engenders is a major barrier to achieving the glycaemic targets known to minimise risk of complications of diabetes.”
BackgroundHypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559 · cited 1×
“In 2003 a Scottish survey found the total cost of hypoglycaemia across a population of about 370 000 (8655 people with diabetes) was just over £92 000 (€110 000, US$140 000).”
BackgroundDonnelly, L. A., Morris, A. D., Frier, B. M., Ellis, J. D., Donnan, P. T., Durrant, R., Band, M. M., Reekie, G., & Leese, G. P. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01501.x · Cited by 511 · cited 1×
“5% of patients experienced at least one episode of severe hypoglycaemia with an incidence of 44 episodes/100 patient years,(23) which is similar to the study by Donnelly et al who reported 35 episodes/100 patient years of severe hypoglycaemia in insulin treated type 2 diabetes.(24) Population based studies from the UK…”
ResultYki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
The effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Abraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., Emanuele, N. V., Levin, S. R., Henderson, W., Lee, H. S., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1113 · Cited by 355
Hypoglycaemia in insulin‐treated Type 2 diabetes: frequency, symptoms and impaired awareness
Henderson, J. N., Allen, K. V., Deary, I. J., & Frier, B. M. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01072.x · Cited by 287
Holstein, A., Plaschke, A., & Egberts, E. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.235 · Cited by 264
Sämann, A., Mühlhauser, I., Bender, R., Kloos, C., & Müller, U. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1905-1 · Cited by 226 · cited 1×
“The cornerstone of diabetes self management is education. Structured education programmes for patients with type 1 diabetes provide patients with the skills necessary to use flexible insulin therapy. The Dusseldorf programmes of Assal and Berger have been shown to improve glucose control with reduction in hypoglycaemi…”
BackgroundCox, D. J., Gonder-Frederick, L. A., Kovatchev, B. P., Julian, D. M., & Clarke, W. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.2.163 · Cited by 226
Brunelle, R. L., Llewelyn, J., Anderson, J. H., Gale, E. A. M., & Koivisto, V. A. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1726 · Cited by 216
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Intensified insulin therapy and the risk of severe hypoglycaemia
Bott, S., Bott, U., Berger, M., & Mühlhauser, I. (1997) · Diabetologia · doi:10.1007/s001250050769 · Cited by 180
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Driving decrements in type I diabetes during moderate hypoglycemia
Cox, D. J., Gonder-Frederick, L., & Clarke, W. (1993) · Diabetes · doi:10.2337/diab.42.2.239 · Cited by 123
Bolli, G. B., Kerr, D., Thomas, R., Torlone, E., Sola-Gazagnes, A., Vitacolonna, E., Selam, J. L., & Home, P. D. (2009) · Diabetes Care · doi:10.2337/dc08-1874 · Cited by 119
Gender differences in counterregulation to hypoglycaemia
Amiel, S. A., Maran, A., Powrie, J. K., Umpleby, A. M., & Macdonald, I. A. (1993) · Diabetologia · doi:10.1007/bf00402284 · Cited by 113
Self-citationCox, D. J., Kovatchev, B., Kovatchev, B., Koev, D., Koeva, L., Dachev, S., Tcharaktchiev, D., Protopopova, A., Gonder-Frederick, L., & Clarke, W. (2004) · International Journal of Behavioral Medicine · doi:10.1207/s15327558ijbm1104_4 · Cited by 88
Effect of Glycemic Control on Glucose Counterregulation During Hypoglycemia in NIDDM
Levy, C. J., Kinsley, B. T., Bajaj, M., & Simonson, D. C. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1330 · Cited by 81
Defining hypoglycaemia: what level has clinical relevance?
Frier, B. M. (2009) · Diabetologia · doi:10.1007/s00125-008-1209-3 · Cited by 71 · cited 1×
“Different studies have used different glucose concentrations to define hypoglycaemia, with most clinicians using a cut-off plasma glucose between 3.5–3.9 mmol/l.”
BackgroundInfluentialDavis, S. N., Shavers, C., & Costa, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6641 · Cited by 69
Delayed Recovery of Cognitive Function Following Hypoglycemia in Adults With Type 1 Diabetes
Zammitt, N. N., Warren, R. E., Deary, I. J., & Frier, B. M. (2008) · Diabetes · doi:10.2337/db07-0695 · Cited by 61 · cited 1×
“This is because following hypoglycaemia, cognitive function remains impaired for up to 30 min after restoration of euglycaemia.(62) It is important for the practitioner certifying for safety to drive to provide the correct information to the DVLA and correct advice to the patient.”
BackgroundGlycemic Parameters with Multiple Daily Injections Using Insulin Glargine Versus Insulin Pump
Garg, S. K., Walker, A. J., Hoff, H. K., D'Souza, A. O., Gottlieb, P. A., & Chase, H. P. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/152091504322783350 · Cited by 60 · cited 1×
“However, most studies in the meta-analysis used older basal insulin regimens. Studies comparing CSII with basal bolus regimens using modern analogue basal insulins do not show any differences in hypoglycaemia.”
ResultIncreasing incidence of serious hypoglycemia in insulin users
JOHNSON, E., KOEPSELL, T., REIBER, G., STERGACHIS, A., & PLATT, R. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00479-6 · Cited by 46
DAFNE Study Group (2003) · Diabetic Medicine · doi:10.1034/j.1600-6143.2003.000987_3.x · Cited by 34
Cited by
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Insulin-pump therapy for type 1 diabetes mellitus
Pickup, J. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1113948 · Cited by 270
Hypoglycemia: The neglected complication
Kalra, S., Mukherjee, J. J., Venkataraman, S., Bantwal, G., Shaikh, S., Saboo, B., Das, A. K., & Ramachandran, A. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117219 · Cited by 255
Choudhary, P., & Amiel, S. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4566-6 · Cited by 52
Self-citationGhandi, K., Pieri, B., Dornhorst, A., & Hussain, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00965-0 · Cited by 34
Metadata
- Authors
- Choudhary, P., & Amiel, S. A.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-04
- Volume
- 87
- Issue
- 1026
- Pages
- 298-306
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2076353291
- Cited by
- 47
- References
- 41
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.